Diltiazem Dosing and Management for Hypertension and Angina

Introduction to Diltiazem

The American College of Cardiology recommends diltiazem dosing for hypertension and angina at 120-360 mg daily, with hypertension often requiring higher doses (up to 360 mg daily) compared to angina (typically 240 mg daily) 1, 2

Dosing Guidelines

Initial dose of diltiazem is 120 mg daily in divided doses or as a single dose with long-acting formulations, as recommended by the American College of Cardiology 1, 3
Maximum maintenance dose of diltiazem is 360 mg daily in divided doses or as a single dose with long-acting formulations, according to the American College of Cardiology and Circulation 1, 2, 3

Contraindications and Precautions

The American College of Cardiology advises avoiding diltiazem in patients with AV block greater than first degree or SA node dysfunction (without pacemaker), hypotension, decompensated systolic heart failure or severe LV dysfunction, and Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation/flutter 1, 3, 4
Diltiazem is a substrate of CYP3A4 (major) and a moderate CYP3A4 inhibitor, and use caution with certain medications such as apixaban, itraconazole, bosutinib, ceritinib, cilostazol, cyclosporine, everolimus, ibrutinib, idelalisib, ivabradine, lomitapide, olaparib, ranolazine, rifampin, and simeprevir, as recommended by the American College of Cardiology 1, 3

Potential Adverse Effects

Hypotension is the most common adverse effect of diltiazem, and worsening heart failure in patients with pre-existing ventricular dysfunction, bradycardia, abnormal liver function tests, and acute hepatic injury are also potential adverse effects, according to the American College of Cardiology and Praxis Medical Insights 1, 3, 4

Monitoring

The American College of Cardiology and Circulation recommend monitoring blood pressure and heart rate, signs and symptoms of heart failure in at-risk patients, liver function tests if clinically indicated, and ECG monitoring in patients with conduction system disease 1, 2, 3, 5

Diltiazem Dosing and Precautions

Contraindications and Precautions

The American Heart Association recommends avoiding diltiazem in patients with sick sinus syndrome, hypotension, or AV block greater than first degree without a pacemaker 6
The American College of Cardiology suggests using diltiazem with caution when combined with beta-blockers, due to the risk of significant bradyarrhythmias and heart failure 7

Clinical Pearls

For hypertension in patients with coronary artery disease, the American College of Cardiology recommends that if beta-blockers are contraindicated, diltiazem may be substituted, but not if there is LV dysfunction 7
When diltiazem is used for hypertension with stable angina, the American Heart Association suggests it can be combined with an ACE inhibitor/ARB and thiazide diuretic if needed for BP control 7

Diltiazem Formulations and Administration

Available Formulations

Diltiazem is available in immediate-release tablets with doses ranging from 30-90 mg 8
Diltiazem can be administered intravenously as a solution, given as an IV bolus of 0.25 mg/kg over 2 minutes or as an IV infusion of 5-15 mg/hour for continuous administration, according to the American College of Cardiology 9

Contraindications and Precautions

The American College of Cardiology recommends avoiding diltiazem in patients with AV block greater than first degree or SA node dysfunction without a pacemaker, as well as in cardiogenic shock 9
Caution should be exercised when using diltiazem in patients with hepatic or renal dysfunction, and when using medications that affect SA/AV nodal conduction, as advised by the American College of Cardiology 9
The American College of Cardiology also notes that diltiazem can worsen heart failure in patients with pre-existing ventricular dysfunction 9

Diltiazem Dosing for Hypertension Management

Initial Dosing and Titration

Titrate diltiazem cautiously and progressively over several weeks to reach effective blood pressure control, as recommended by the European Heart Journal 10

Safety and Monitoring

The American Heart Association, as published in Circulation, recommends monitoring blood pressure and heart rate regularly during dose titration and watching for common adverse effects including hypotension, bradycardia, peripheral edema, and constipation 11
Use caution in patients with bradycardia, as this may be dose-limiting, according to Circulation 11

Special Considerations

For patients with relative tachycardia, diltiazem may be preferred over other calcium channel blockers like nifedipine, as suggested by the European Heart Journal 10
Adding diuretics may help manage peripheral edema side effects, as noted in the European Heart Journal 10

Diltiazem Contraindications and Precautions

Absolute Contraindications

The American College of Cardiology recommends that diltiazem is contraindicated in patients with second or third-degree AV block without a functioning ventricular pacemaker, and in patients with Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation/flutter, and in patients with decompensated systolic heart failure or severe LV dysfunction 12, 13
The American College of Cardiology also recommends that diltiazem is contraindicated in patients with cardiogenic shock 14

Use with Caution (Relative Contraindications)

The American College of Cardiology suggests that diltiazem should be used with caution in patients with hepatic dysfunction, as it is metabolized by the liver, and in patients with renal dysfunction, as it may require dose adjustment 14
The American College of Cardiology recommends that diltiazem should be used with caution in patients taking medications with SA/AV nodal-blocking properties, due to the increased risk of conduction abnormalities 14

Drug Interactions to Consider

The American College of Cardiology warns that diltiazem is both a substrate of CYP3A4 and a moderate CYP3A4 inhibitor, and should be used with caution in patients taking CYP3A4 substrates and inhibitors, such as apixaban, itraconazole, bosutinib, ceritinib, cilostazol, cyclosporine, and everolimus 12

Diltiazem Formulations

Pharmacokinetics and Dosing

The American Heart Association recommends Cardizem CD, an extended-release, once-daily formulation, for controlled delivery over 24 hours, with dosing ranging from 180-420 mg for hypertension and angina 15, 16
The once-daily CD formulation is designed to maintain consistent blood levels over 24 hours, with a starting dose of 120-180 mg once daily, titrated to a maximum of 360-420 mg daily 15

Diltiazem Extended-Release Dosing Guidelines

Contraindications and Precautions

The American Heart Association recommends avoiding diltiazem in patients with second or third-degree AV block without a functioning pacemaker, sick sinus syndrome without a pacemaker, decompensated systolic heart failure or severe left ventricular dysfunction, and hypotension 17
The American Heart Association also recommends avoiding routine combination of diltiazem with beta-blockers due to increased risk of bradycardia and heart block 17

Special Populations

The European Respiratory Society suggests that diltiazem is preferred over dihydropyridines in patients with baseline tachycardia, as it reduces heart rate at rest and during exercise 18

Monitoring Requirements

The American Heart Association recommends reassessing patients in 1 month after initiation or dose change of diltiazem, and monitoring for return of symptoms such as elevated blood pressure, angina, and rapid heart rate 17

Common Adverse Effects

The American Heart Association notes that peripheral edema is a dose-related adverse effect of diltiazem, more common in women, and considers adding diuretics 17
The American Heart Association also warns of significant bradyarrhythmias, especially when combining diltiazem with beta-blockers 17

Long-Acting Oral Diltiazem Formulations

Available Formulations

The American Heart Association recommends long-acting oral diltiazem formulations, available as extended-release (ER) or controlled-delivery (CD) formulations, dosed once daily at 120-540 mg, with slow-release preparations also available for divided dosing at 120-360 mg daily 19, 20, 21, 22
The standard dosing range for most indications is 120-360 mg once daily, with doses up to 540 mg/day studied and found safe for hypertension 19, 20, 21, 22
Slow-release tablets are available for divided dosing at 120-360 mg daily in 2-3 divided doses 19, 20, 22
The onset of action for slow-release tablets is 2-4 hours with maintenance dosing 19, 22

Contraindications

The American College of Cardiology contraindicates the use of diltiazem in second/third-degree AV block without pacemaker, decompensated heart failure, severe LV dysfunction, and WPW syndrome with atrial fibrillation 21

Diltiazem Dosing and Contraindications

Introduction to Diltiazem Therapy

The American Heart Association recommends exercising caution when combining diltiazem with beta-blockers due to the risk of significant bradyarrhythmias and heart failure 23
The European Society of Cardiology suggests that diltiazem is preferred over dihydropyridines in patients with baseline tachycardia 24

Contraindications and Cautions

The American College of Cardiology advises against using diltiazem in patients with second- or third-degree AV block without a functioning pacemaker, sick sinus syndrome without a pacemaker, decompensated systolic heart failure or severe left ventricular dysfunction, cardiogenic shock, Wolff-Parkinson-White syndrome with atrial fibrillation/flutter, or hypotension 23
The American Heart Association recommends avoiding routine combination with beta-blockers due to increased risk of bradycardia and heart block, and using diltiazem with caution in patients with PR interval >0.24 seconds 23

Special Clinical Situations

The European Heart Journal suggests that diltiazem is effective and well-tolerated in elderly patients (65-85 years) with mild-to-moderate hypertension, although the cited reference is ignored, another reference from the same journal is used 24
The American College of Cardiology recommends using diltiazem for continuing or recurrent ischemia when beta-blockers are contraindicated, not successful, or cause unacceptable side effects, but advises against using it in patients with clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second/third-degree AV block without a pacemaker 23

Diltiazem Dosage and Administration

Special Considerations

The American Heart Association, as published in Circulation, suggests that diltiazem can substitute for beta-blockers in hypertensive patients with chronic stable angina, but not if left ventricular dysfunction is present, with a strength of evidence based on clinical trials 25
The American Heart Association, as published in Circulation, also recommends exercising extreme caution when combining diltiazem with beta-blockers due to increased risk of significant bradyarrhythmias and heart failure, highlighting the need for close monitoring 25

Management of Diltiazem in Patients with Low Blood Pressure

Introduction to Diltiazem Management

The European Society of Cardiology recommends that asymptomatic low blood pressure does not usually require any change in therapy, including for patients on calcium channel blockers like diltiazem 26
The American Heart Association and other guideline societies imply that a blood pressure of 115/60 mmHg is within target range for patients with hypertension, with a target of less than 130/80 mmHg per 2020 guidelines 27, 28, 29

Key Decision Points for Diltiazem Use

The European Society of Cardiology states that asymptomatic low blood pressure, such as 115/60 mmHg, does not require medication adjustment, including for diltiazem 30, 26
For patients prescribed diltiazem for atrial fibrillation rate control, heart rate is more important than blood pressure 26
For patients prescribed diltiazem for hypertension, a BP of 115/60 is within target range, with a target of less than 130/80 mmHg per 2020 ISH guidelines 27, 28, 29

Monitoring and Adjusting Diltiazem

Patients should assess for dizziness or lightheadedness when standing before taking diltiazem, as symptomatic hypotension may require dose adjustment or reconsideration of other vasodilators 30, 26
Patients should also monitor for confusion or altered mental status, as well as signs of worsening heart failure, such as increased shortness of breath, weight gain, or edema 30, 26
For patients on concurrent beta-blockers, heart rate should be monitored before dosing due to the risk of excessive bradycardia 30, 26

Special Considerations for Diltiazem Use

The European Society of Cardiology recommends that diltiazem should generally be avoided in patients with heart failure with reduced ejection fraction due to negative inotropic effects, but if already prescribed, asymptomatic low BP alone is not a reason to stop 26
Elderly or frail patients may be more susceptible to symptomatic hypotension even at higher BP readings, so symptom assessment is particularly important 29

Contraindications and Precautions for Diltiazem Use

Absolute Contraindications

The American Heart Association recommends that diltiazem is absolutely contraindicated in patients with second- or third-degree AV block without a pacemaker, sick sinus syndrome without a pacemaker, hypotension with systolic BP <90 mmHg, acute MI with pulmonary congestion, decompensated heart failure or severe LV dysfunction, and Wolff-Parkinson-White syndrome with atrial fibrillation/flutter 31, 32
The American College of Cardiology states that second- or third-degree AV block without a functioning ventricular pacemaker is a contraindication for diltiazem use 31, 32, 33
First-degree AV block with PR interval >0.24 seconds is a contraindication for diltiazem use in acute coronary syndromes, as recommended by the American Heart Association 33, 34

Critical Relative Contraindications

The American Heart Association advises that concurrent beta-blocker therapy poses significant risk for symptomatic bradycardia, profound AV block, and heart failure when used with diltiazem 31, 35, 36, 34
The American College of Cardiology recommends that diltiazem should not be given for wide-complex tachycardias unless the arrhythmia is known with certainty to be supraventricular in origin 31

Specific Clinical Scenarios

The American Heart Association suggests that diltiazem should not be used as first-line therapy for cocaine-associated acute coronary syndromes; instead, reserve it for patients unresponsive to benzodiazepines and nitroglycerin, and avoid in patients with heart failure or LV dysfunction 37

Important Clinical Pitfalls

The American College of Cardiology notes that diltiazem is both a CYP3A4 substrate and moderate CYP3A4 inhibitor, and exercise caution is advised when using it with certain medications, such as apixaban, itraconazole, and simvastatin 32
The American Heart Association recommends reducing warfarin dose by 50% and digoxin dose by 30-50% when initiating diltiazem 32

Acute Coronary Syndromes

The American College of Cardiology states that short-acting nifedipine should never be used in acute coronary syndromes and showed increased mortality 35, 33, 34
The American Heart Association recommends that diltiazem should not be used routinely in STEMI, and in non-STEMI/unstable angina, use only when beta-blockers are contraindicated AND there is no severe LV dysfunction 35, 36, 33, 34

Diltiazem for Hypertension Management

Introduction to Diltiazem Therapy

The American Heart Association recommends avoiding diltiazem in patients with heart failure with reduced ejection fraction due to negative inotropic effects, classified as a Class III (Harm) recommendation 38
Diltiazem is an effective and appropriate treatment for hypertension, particularly in patients with comorbid angina or supraventricular tachycardia, and appears safe in patients with impaired renal function—however, it must be avoided in patients with systolic heart failure or significant left ventricular dysfunction 39, 38

Clinical Considerations

The European Heart Journal suggests that diltiazem is preferred over dihydropyridine calcium channel blockers when resting heart rate is elevated 40
Diltiazem slows atrioventricular nodal conduction, making it particularly valuable for rate control in atrial fibrillation or AVNRT 41, 42

Contraindications and Precautions

The American Heart Association advises against using diltiazem in patients with decompensated systolic heart failure or severe left ventricular dysfunction 39, 38, 42
Diltiazem should be used with caution in combination with beta-blockers due to the increased risk of significant bradyarrhythmias, profound AV block, and heart failure 40

Diltiazem Dosing Guidelines

Introduction to Diltiazem Therapy

The American College of Cardiology recommends starting diltiazem at 120 mg daily and titrating up to a maximum of 360 mg daily for oral therapy, with hypertension typically requiring higher doses than angina 43

Oral Dosing for Chronic Conditions

The American College of Cardiology suggests that for hypertension, doses of 240-360 mg daily are typically required for adequate blood pressure control, and for angina, 240 mg daily is typically sufficient, although specific dosing may vary based on individual patient needs 43

Absolute Contraindications

The American College of Cardiology advises against using diltiazem in patients with second- or third-degree AV block without a functioning pacemaker, sick sinus syndrome without a pacemaker, decompensated systolic heart failure or severe left ventricular dysfunction, hypotension, cardiogenic shock, or Wolff-Parkinson-White syndrome with atrial fibrillation/flutter 43

Critical Precautions and Drug Interactions

The American College of Cardiology warns that diltiazem is both a CYP3A4 substrate and a moderate CYP3A4 inhibitor, and exercise caution is advised when combining with certain medications, such as apixaban, itraconazole, and simvastatin 43

Common Adverse Effects

The American College of Cardiology notes that hypotension is the most common adverse effect of diltiazem, especially with IV administration, and other common adverse effects include peripheral edema, bradycardia, and worsening heart failure in patients with pre-existing ventricular dysfunction 43

Converting from Immediate-Release to Extended-Release Diltiazem

Dosage and Administration

The American Heart Association recommends a starting dose of 120-180 mg once daily for extended-release diltiazem 44, 45
The usual maintenance range for extended-release diltiazem is 120-360 mg once daily, as recommended by the American College of Cardiology 44, 46, 47

Pharmacokinetics

The half-life of extended-release diltiazem is 12 hours, compared to 4.5-12 hours for immediate-release diltiazem 47
Extended-release formulations provide consistent 24-hour drug delivery, allowing for once-daily administration 44

Contraindications and Warnings

The American College of Cardiology advises against converting patients with second- or third-degree AV block without a functioning pacemaker, sick sinus syndrome without a pacemaker, decompensated systolic heart failure, or severe left ventricular dysfunction 44, 47
Exercise extreme caution when combining extended-release diltiazem with beta-blockers due to increased risk of significant bradyarrhythmias, profound AV block, and heart failure 44

Drug Interactions

Monitor levels of apixaban, rivaroxaban, simvastatin, cyclosporine, and other CYP3A4 substrates when initiating diltiazem, as recommended by the American Heart Association 47

Significant Drug Interactions Reducing Diltiazem Exposure

Rifamycin Antibiotics

Co‑administration of rifamycin antibiotics (e.g., rifampin, rifabutin, rifapentine) markedly lowers diltiazem plasma concentrations by inducing CYP3A4 metabolism, potentially compromising therapeutic efficacy; clinicians should consider switching to an alternative cardiovascular agent when these antibiotics are required. 48, 49

Safety Considerations for Abrupt Discontinuation of Diltiazem

Comparison with Other Agents

Central α‑agonists such as clonidine can precipitate severe rebound hypertension when stopped suddenly, therefore they require a gradual taper. This contrast highlights that diltiazem does not share this rebound risk. [50][51]

Contraindications in Acute Coronary Syndromes

Abruptly stopping diltiazem is contraindicated in patients experiencing an acute coronary syndrome or unstable angina unless an alternative anti‑ischemic therapy is instituted, because loss of rate control and coronary vasodilation may worsen myocardial ischemia. 52

Rate‑Control Management in Atrial Fibrillation

For patients with poorly controlled atrial fibrillation, an alternative rate‑control medication should be started before discontinuing diltiazem to prevent a symptomatic rapid ventricular response. 53

Combination Therapy of Diltiazem and Losartan for Hypertension

Guideline Endorsement

The 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines designate the combination of a non‑dihydropyridine calcium‑channel blocker (diltiazem) with an angiotensin‑receptor blocker (losartan) as a preferred therapeutic strategy for patients with hypertension, reflecting a strong (Class I) recommendation. 54

Safety Considerations

The ESH/ESC Guidelines caution that non‑dihydropyridine calcium antagonists such as diltiazem should not be combined with beta‑blockers, because this pairing can precipitate severe bradyarrhythmias, AV block, and worsening heart failure; the guideline therefore limits beta‑blocker combinations to dihydropyridine agents. 54
A 2022 study published in Hypertension identified the principal safety pitfall of diltiazem as its concurrent use with beta‑blockers—not with losartan—highlighting risks of profound AV block, symptomatic bradycardia requiring pacemaker implantation, and exacerbation of heart failure due to additive negative inotropic effects. 55

Drug‑Interaction Alerts

Diltiazem is a moderate CYP3A4 inhibitor and substrate; co‑administration with direct oral anticoagulants (e.g., apixaban, rivaroxaban) can increase plasma anticoagulant concentrations and elevate bleeding risk, as reported in the 2022 Hypertension article. 55

Clinical Situations Where the Combination Is Particularly Useful

The 2022 Hypertension evidence suggests the diltiazem‑losartan regimen is especially advantageous in hypertensive patients who also have:

Diltiazem Formulation‑Specific Dosing Recommendations

Recommended Dosing Frequency by Product Type

The capsule formulation of diltiazem extended‑release is generally administered twice daily to three times daily, whereas extended‑release tablets are intended for once‑daily dosing. 56

Diltiazem Formulation Conversion: Immediate‑Release Dosing Guidelines

Recommended Dosing Conversion

For patients currently on 120 mg once‑daily extended‑release diltiazem, convert to immediate‑release tablets 30 mg taken four times daily (total 120 mg/day) to preserve the same total daily dose and achieve equivalent 24‑hour coverage. (American College of Cardiology) 57
An alternative regimen of 40 mg three times daily (total 120 mg/day) may be employed when four‑times‑daily dosing is impractical, though it provides less consistent plasma concentrations. (American College of Cardiology) 57

Dosing Rationale per Guidelines

The American College of Cardiology specifies that immediate‑release diltiazem is dosed at 30–90 mg four times daily, whereas extended‑release formulations are dosed at 120–360 mg once daily; the key principle is maintaining the same total daily dose when switching formulations. (American College of Cardiology) 57
Immediate‑release 30 mg four times daily delivers comparable 24‑hour therapeutic coverage to a single 120 mg extended‑release dose. (American College of Cardiology) 57

Clinical Situations Favoring Immediate‑Release Use

Hospitalized patients who need flexible dosing schedules or who are transitioning to intravenous therapy may benefit from immediate‑release diltiazem. (American College of Cardiology) 57

Safety Contraindications (apply to both formulations)

Do not use diltiazem in patients with second‑ or third‑degree atrioventricular block without a functioning pacemaker, sick‑sinus syndrome without a pacemaker, decompensated systolic heart failure, severe left‑ventricular dysfunction, cardiogenic shock, or Wolff‑Parkinson‑White syndrome with atrial fibrillation/flutter. (American College of Cardiology) 57

Drug Interaction Warning

Concurrent beta‑blocker therapy should be avoided because of an increased risk of profound AV block, symptomatic bradycardia, and worsening heart failure. (American College of Cardiology) 57

Common Pitfall to Avoid

A 120 mg once‑daily immediate‑release dose does not provide adequate 24‑hour coverage; immediate‑release diltiazem must be divided into multiple daily doses (typically four) to match the pharmacokinetic profile of the extended‑release formulation. (American College of Cardiology) 57

Diltiazem Dosing Adjustments in Hepatic and Renal Impairment

Hepatic Impairment

In patients with hepatic dysfunction, diltiazem clearance is markedly reduced, leading to a prolonged elimination half‑life and necessitating dose reduction to avoid toxicity. 58

Renal Impairment

Renal dysfunction does not significantly change diltiazem pharmacokinetics; therefore, no routine dose adjustment is required for patients with severe renal failure, although clinical caution is advised. 59